IL72545A - Liposomes comprising anti-microbial agents and their preparation - Google Patents

Liposomes comprising anti-microbial agents and their preparation

Info

Publication number
IL72545A
IL72545A IL72545A IL7254584A IL72545A IL 72545 A IL72545 A IL 72545A IL 72545 A IL72545 A IL 72545A IL 7254584 A IL7254584 A IL 7254584A IL 72545 A IL72545 A IL 72545A
Authority
IL
Israel
Prior art keywords
liposomes
preparation
microbial agents
microbial
agents
Prior art date
Application number
IL72545A
Other languages
English (en)
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of IL72545A publication Critical patent/IL72545A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL72545A 1983-08-01 1984-07-30 Liposomes comprising anti-microbial agents and their preparation IL72545A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51891283A 1983-08-01 1983-08-01
US06/633,481 US5000958A (en) 1983-08-01 1984-07-26 Enhancement of pharmaceutical activity

Publications (1)

Publication Number Publication Date
IL72545A true IL72545A (en) 1987-11-30

Family

ID=27059635

Family Applications (1)

Application Number Title Priority Date Filing Date
IL72545A IL72545A (en) 1983-08-01 1984-07-30 Liposomes comprising anti-microbial agents and their preparation

Country Status (11)

Country Link
US (1) US5000958A (xx)
EP (1) EP0153364B1 (xx)
AU (1) AU3219484A (xx)
CA (1) CA1237671A (xx)
DE (1) DE3483322D1 (xx)
ES (1) ES8603264A1 (xx)
IL (1) IL72545A (xx)
IT (1) IT1179029B (xx)
PT (1) PT79012A (xx)
SG (1) SG18592G (xx)
WO (1) WO1985000515A1 (xx)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588299B2 (en) * 1985-04-08 1989-09-14 Rafa Laboratories Ltd. Artificial microcompartmentalization
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
WO1987000043A1 (en) * 1985-07-05 1987-01-15 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
FR2628317B1 (fr) * 1988-03-09 1991-11-08 Lvmh Rech Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de scutellaria, ou au moins un flavonoide tel que baicaleine ou baicaline et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite anti-allergique, anti-inflammatoire ou anti-vieillissement, l'incorporant
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
EP0414806B1 (en) * 1988-05-20 1994-07-20 The Liposome Company, Inc. High ratio active agent:lipid complex
IL90561A (en) * 1988-06-08 1993-08-18 Fountain Pharm Inc Method for making solvent dilution microcarriers
US5269979A (en) * 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
AU4525589A (en) * 1988-10-27 1990-05-14 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
ES2116983T3 (es) * 1989-05-25 1998-08-01 Technology Unlimited Inc Ahuyentador de insectos.
ZA911974B (en) * 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
EP0624095B2 (en) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Methods and compositions for reducing blood loss
EP0585514B1 (en) * 1992-01-09 1998-10-07 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d., Ljubljana Animal feed and an additive thereto or to drinking water containing an antibiotic mixture of gentamicin with lincomycin or clindamycin
US5344822A (en) * 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
WO1994012155A1 (en) * 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process
US5759571A (en) * 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5478819A (en) * 1993-06-23 1995-12-26 Simo Tarpila Phospholipid composition and use thereof
JPH09502987A (ja) * 1993-09-22 1997-03-25 ゾーマ コーポレイション 殺菌性／浸透性が向上した（ｂｐｉ）タンパク質生成物および抗生物質の投与によるグラム陰性細菌感染の治療方法
EP0664117A1 (de) * 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposomenlösungen
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6183774B1 (en) 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
WO1997044356A2 (en) 1996-05-08 1997-11-27 Biogen, Inc. RET LIGAND (RetL) FOR STIMULATING NEURAL AND RENAL GROWTH
AU4151697A (en) * 1996-08-14 1998-03-06 Vanderbilt University Compositions of antichlamydial agents for the diagnosis and management of infection caused by (chlamydia)
US5935572A (en) * 1997-01-10 1999-08-10 Collaborative Laboratories, Inc. Composition containing protease separate from glycosidase for removing nits in treating lice infestation
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US20030130169A1 (en) * 2001-10-01 2003-07-10 The Board Of Trustees Of The University Of Illinois Methods of treating drug-resistant bacterial infections
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
WO2003070181A2 (en) * 2002-02-19 2003-08-28 Eden Research Plc Compositions and methods for preservation of food
JP2005525375A (ja) * 2002-03-05 2005-08-25 トランセイブ， インク． 生物活性物質をリポソーム又は脂質複合体内に封入する方法
CA2504317C (en) * 2002-10-29 2012-05-22 Transave, Inc. Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US6846966B2 (en) * 2002-11-26 2005-01-25 Exxonmobil Chemical Patents Inc. Method and apparatus for treating oxygenate-containing feeds and their use in conversion of oxygenates to olefins
FR2852513A1 (fr) * 2003-03-17 2004-09-24 Groupe Lepine Combinaison d'antibiotiques gentamicine/clindamycine et ses applications aux ciments orthopediques curatifs
WO2004089969A2 (en) 2003-04-02 2004-10-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
WO2005095450A2 (en) 2004-03-30 2005-10-13 Nsgene A/S Therapeutic use of a growth factor, nsg33
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
WO2006032136A1 (en) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Branch Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
DE102005063375A1 (de) * 2005-09-15 2007-04-19 Schülke & Mayr GmbH Antimikrobielle Zubereitungen mit einem Gehalt an Octenidindihydrochlorid verkapselt in Liposomen
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US20100196455A1 (en) * 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US8470762B2 (en) * 2007-05-31 2013-06-25 Colgate-Palmolive Company Fabric softening compositions comprising polymeric materials
WO2009108407A1 (en) * 2008-02-25 2009-09-03 The University Of North Carolina At Charlotte Office Of Technology Transfer Biodegradable therapeutic nanoparticles containing an antimicrobial agent
CA2718170A1 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
EP2512240B1 (en) 2009-12-18 2018-04-11 Achelios Therapeutics, Inc. Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
JP2013532144A (ja) 2010-06-14 2013-08-15 ハー・ルンドベック・アクチエゼルスカベット ＳｏｒＬＡとＧＤＮＦファミリーリガンド受容体の間の相互作用の調節
US9212201B2 (en) * 2010-07-23 2015-12-15 Acea Biotech, Inc. Antifungal and antiparasitic polyene macrolides
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
NZ719739A (en) 2012-05-21 2017-07-28 Insmed Inc Systems for treating pulmonary infections
EP3581186A1 (en) 2012-11-29 2019-12-18 Insmed Incorporated Stabilized vancomycin formulations
PT3142643T (pt) 2014-05-15 2019-10-28 Insmed Inc Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
WO2015188140A1 (en) 2014-06-06 2015-12-10 The Curators Of The University Of Missouri Enhancement of antibiotic efficacy
WO2016089893A1 (en) 2014-12-01 2016-06-09 Achelios Therapeutics Inc. Methods and compositions for treating migraine and conditions associated with pain
AU2016301282B2 (en) 2015-08-03 2022-03-17 Children's Medical Center Corporation Charged ion channel blockers and methods for use
EP3500581A4 (en) 2016-08-17 2021-10-06 Solstice Biologics, Ltd. POLYNUCLEOTIDE CONSTRUCTS
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11377422B2 (en) 2019-03-11 2022-07-05 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
AU2020237474A1 (en) 2019-03-11 2021-09-30 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
SG11202109713PA (en) 2019-03-11 2021-10-28 Nocion Therapeutics Inc Ester substituted ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US20220307013A1 (en) 2019-08-30 2022-09-29 The Regents Of The University Of California Gene fragment overexpression screening methodologies, and uses thereof
WO2021091586A1 (en) 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
KR20220123381A (ko) 2019-11-06 2022-09-06 녹시온 테라퓨틱스 인코포레이티드 하전된 이온 채널 차단제 및 사용 방법
IL295950A (en) 2020-03-11 2022-10-01 Nocion Therapeutics Inc Charged ion channel blockers and methods of use
KR20240006581A (ko) 2021-05-06 2024-01-15 호바 세라퓨틱스 에이피에스 화학요법-유도된 신경병성 통증의 예방 및 치료
AU2022405685A1 (en) 2021-12-10 2024-07-11 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5231981A (en) * 1975-08-18 1977-03-10 Takeda Chem Ind Ltd Microcapsule preparation method
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4328222A (en) * 1978-11-21 1982-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions for parenteral or local administration
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase

Also Published As

Publication number Publication date
EP0153364B1 (en) 1990-09-26
ES542147A0 (es) 1985-12-16
DE3483322D1 (de) 1990-10-31
WO1985000515A1 (en) 1985-02-14
ES8603264A1 (es) 1985-12-16
EP0153364A1 (en) 1985-09-04
AU3219484A (en) 1985-03-04
US5000958A (en) 1991-03-19
EP0153364A4 (en) 1987-03-03
IT1179029B (it) 1987-09-16
PT79012A (en) 1984-09-01
IT8467767A0 (it) 1984-08-01
CA1237671A (en) 1988-06-07
SG18592G (en) 1992-04-16
IT8467767A1 (it) 1986-02-01

Similar Documents

Publication Publication Date Title
IL72545A (en) Liposomes comprising anti-microbial agents and their preparation
GB2099301B (en) Antimicrobial carpet and preparation thereof
GB8304165D0 (en) Preparing liposomes and products
GB2145422B (en) Novel poly-esters their preparation and pharmacolgical use thereof
IL68250A (en) Plurilamellar vesicles and their preparation
PH19602A (en) Phenyl aliphatic-isoxazoloes useful as antiviral agents and preparation thereof
IL73041A0 (en) 1,3-diaryl-5-methylene-perhydropyrimidin-2-ones,their preparation and their use as herbicides
GB2138292B (en) Haloalkynes and their use as fungicides
CY1522A (en) 1-pyrimidinyloxy-3-hetarylalkylamino-2-propanols preparation and uses
IL71658A (en) 17-sulfonylmethylene-steroids and their preparation
DE3367089D1 (en) 3-phenoxy-1-azetidinecarboxamides and their use and preparation
ZA842202B (en) Phenylaminobenzenealkanols and preparation
GB2138293B (en) Novel pesticidal compositions and their use
IL73876A0 (en) Acylamino-mitosanes and their preparation
EP0298706A3 (en) Glycans and their use as anti-viral agents
GB2117757B (en) Alkylspectinomycins and their preparation
GB2146329B (en) Naphthalenylimidazopyridine and derivatives and their preparation
GB9027864D0 (en) Pyrimidinyl-and triazinyl-salicylamides and their use and preparation
DE3366497D1 (en) Antibacterial agents, their preparation and use
GB2126230B (en) Substituted 1-pyridyloxy-3-indolylalkylamino-2-propanols preparation and use thereof
DE3477007D1 (en) Heat-sensitizing agents, their preparation and use
GR80455B (en) 3-azidocephalosporins as intremediates and novel antibacterial agents
GB2129001B (en) Epoxycarbacyclin derivatives their preparation and use
GB8410462D0 (en) Skin preparation composition
ZA849174B (en) Halonitriles and their preparation